durable responses to ibrutinib and venetoclax in r/r mcl: 3-year aim update
Published 4 years ago • 77 plays • Length 3:06Download video MP4
Download video MP3
Similar videos
-
1:21
ibrutinib, rituximab and venetoclax in the treatment of patients with newly diagnosed mcl
-
5:34
venetoclax added to ibrutinib in patients with cll with molecular resistance to btki treatment
-
1:39
the safety of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (vipor) in r/r mcl
-
3:28
the sympatico trial: ibrutinib plus venetoclax in tp53-mutated mcl
-
3:07
ibrutinib venetoclax in treatment-naïve wm: results from a phase ii trial
-
1:09
ibrutinib added to autosct conditioning and consolidation for patients with abc-dlbcl
-
2:23
zilo-301: phase iii study of zilovertamab ibrutinib vs ibrutinib in r/r mcl
-
1:36
improve study update: safety and efficacy of venetoclax retreatment in r/r cll
-
5:42
promising therapeutic efficacy of ebv-specific t-cell immunotherapy tabelecleucel in ptld
-
3:46
evaluating teclistamab step-up dosing & dose de-escalation in r/r myeloma in the real-world setting
-
6:28
cytoquest™ cr ctc enrichment - rbc lysis
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
-
1:44
triangle: ibrutinib with soc or as a substitute to autologous transplantation in first-line mcl
-
4:31
sequence of administration of ibrutinib with obinutuzumab in r/r cll patients
-
2:38
ibrutinib treatment for cll does not increase the incidence of richter’s transformation
-
3:27
venetoclax: an unmet need in r/r mantle cell lymphoma after btk inhibitors
-
2:20
the effect of ibrutinib dose-reduction on outcomes of patients with cll/sll: real-world evidence
-
2:09
heart transplantation in attr amyloidosis
-
2:00
ibrutinib: use in small cll subgroups only?
-
1:51
the safety and efficacy of retreatment with venetoclax plus rituximab in r/r cll
-
0:53
go-flag: bridge therapy to allo-sct in r/r aml